Abstracts tagged "Raynaud’s phenomenon and systemic sclerosis"

Abstract Number: 2595 • 2013 ACR/ARHP Annual Meeting
Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease
Cintia Camargo, Juliana Sekiyama, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: To analyze the morphological and functional abnormalities of the microcirculation through widefield nailfold capillaroscopy (NFC), videocapillaroscopy and cutaneous microvascular blood flow measurement before and…
Abstract Number: 707 • 2013 ACR/ARHP Annual Meeting
Different Location and Extent Of Impaired Perfusion Of The Choroid Plexus In Primary and Secondary Raynaud’s Phenomenon
Francesca Ingegnoli¹, Roberta Gualtierotti², Luisa Pierro³, Elisabetta Miserocchi⁴, Giulio Modorati⁵, Claudia Del turco³, Marco Gagliardi³, Giuseppe Parrinello⁶, Tommaso Schioppo² and Pier Luigi Meroni⁷, ¹Dept. of clinical sciences and community health, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ²Dept. of clinical sciences and community health, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ³Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, ⁴Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, ⁵San Raffaele Scientific Institute, Ocular immunology and uveitis service, Milano, Italy, ⁶Department of Ophthalmology,, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, ⁷Division of Rheumatology, Gaetano Pini Institute, Milano, Italy
Background/Purpose: Raynaud’s phenomenon (RP) is a disorder characterized by systemic vascular dysregulation which has been related with vasospasms and retinal blood flow abnormalities. Nevertheless among…
Abstract Number: 706 • 2013 ACR/ARHP Annual Meeting
Effect Of Aminaftone On Raynaud’s Phenomenon Secondary To Systemic Sclerosis: A Double-Blind Prospective, Randomized, Placebo-Controlled Pilot Study
Alessandro Santaniello¹, Barbara Vigone², Monica Caronni² and Lorenzo Beretta³, ¹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
Background/Purpose: Raynaud’s phenomenon (RP) is a pivotal manifestation of systemic sclerosis (SSc) which reflects an underlying vasculopathy. Endothelial activation with increased circulating levels of Endothelin-1…
Abstract Number: 1481 • 2012 ACR/ARHP Annual Meeting
A Double-Blind Placebo-Controlled Crossover Trial of the Alpha-_2C Adrenoceptor Antagonist Orm-12741 for Prevention of Cold-Induced Vasospasm in Patients with Systemic Sclerosis
Ariane Herrick¹, Andrea Murray², Angela Ruck³, Juha Rouru⁴, Tonia Moore², John Whiteside³, Pasi Hakulinen⁴, Fredrick M. Wigley⁵ and Amir Snapir⁴, ¹Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, ²School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ³Orion Pharma UK, Research & Development, Nottingham, United Kingdom, ⁴Orion Corporation Orion Pharma, Turku, Finland, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The alpha-2C adrenoceptor is thought to play a key role in mediating cold-induced vasospasm in the digits. A previous study suggested that in patients…
Abstract Number: 1482 • 2012 ACR/ARHP Annual Meeting
Laser Speckle Contrast Imaging May Help in the Differential Diagnosis of Raynaud’s Phenomenon
Alessandra Della Rossa¹, Massimiliano Cazzato¹, Walter Bencivelli¹, Anna d'Ascanio², Marta Mosca¹ and Stefano Bombardieri³, ¹Internal Medicine, Rheumatology Unit, Pisa, Italy, ²Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Department of Internal Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: to investigate blood flow and microvascular reactivity by laser speckle perfusion imager (Perimed, Jarfalla) in consecutive patients affected by Raynaud’s phenomenon at baseline and…
Abstract Number: 1472 • 2012 ACR/ARHP Annual Meeting
Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis
Francesca Ingegnoli¹, Roberta Gualtierotti², Tommaso Schioppo², Annalisa Orenti³, Patrizia Boracchi³, Chiara Lubatti¹, Sara Lodi Rizzini¹, Antonella Murgo¹, Silvana Zeni⁴, Claudio Mastaglio⁵, Valentina Galbiati⁶, Claudia Grossi⁷, Maria Borghi⁷, William M. Rosenberg⁸ and Pier Luigi Meroni⁹, ¹Dept. of clinical and community science, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ²Dept. of clinical sciences and community health, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ³Dept. of clinical and community science, Medical Statistics and Biometry, University of Milan, Milano, Italy, ⁴Division of Rheumatology, Istituto G. Pini, Milano, Italy, ⁵Moriggia-Pelascini, Gravedona, Italy, ⁶Rheumatology Unit, Ospedale Moriggia-Pelascini, Italia Hospital, Gravedona, Italy, ⁷Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁸Centre for Hepatology - UCL, London, United Kingdom, ⁹Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: Enhanced Liver Fibrosis (ELF) test is derived from an algorithm of 3 serum biomarkers of fibrosis (i.e. tissue inhibitors of matrix metalloproteinases, hyaluronic acid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].